• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ATYR

    aTyr Pharma Inc.

    Subscribe to $ATYR
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2015

    Exchange: NASDAQ

    Recent Analyst Ratings for aTyr Pharma Inc.

    DatePrice TargetRatingAnalyst
    2/18/2025$16.00Outperform
    Leerink Partners
    1/6/2025Overweight
    Cantor Fitzgerald
    10/4/2024$17.00Overweight
    Wells Fargo
    9/5/2024$9.00Buy
    Jefferies
    See more ratings

    aTyr Pharma Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on aTyr Pharma with a new price target

      Leerink Partners initiated coverage of aTyr Pharma with a rating of Outperform and set a new price target of $16.00

      2/18/25 7:06:32 AM ET
      $ATYR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on aTyr Pharma

      Cantor Fitzgerald initiated coverage of aTyr Pharma with a rating of Overweight

      1/6/25 8:58:50 AM ET
      $ATYR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on aTyr Pharma with a new price target

      Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00

      10/4/24 7:17:27 AM ET
      $ATYR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on aTyr Pharma with a new price target

      Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00

      9/5/24 7:38:51 AM ET
      $ATYR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care